Vertex Pharmaceuticals Incorporated

NASDAQ

Market Cap.

109.14B

Avg. Volume

1.64M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated News

Vertex Pharmaceuticals Incorporated Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
vrtx.com

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated Earnings & Revenue

Vertex Pharmaceuticals Incorporated Financials

Table Compare

Compare VRTX metrics with:

   

Earnings & Growth

VRTX

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

VRTX

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

VRTX

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

VRTX

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Vertex Pharmaceuticals Incorporated Income

Vertex Pharmaceuticals Incorporated Balance Sheet

Vertex Pharmaceuticals Incorporated Cash Flow

Vertex Pharmaceuticals Incorporated Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Vertex Pharmaceuticals Incorporated Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Vertex Pharmaceuticals Incorporated Executives

NameRole
Dr. Reshma Kewalramani FASN, M.D.Chief Executive Officer, President & Director
Mr. Stuart A. Arbuckle B.Sc.Executive Vice President & Chief Operating Officer
Mr. Charles F. Wagner Jr.Executive Vice President & Chief Financial Officer
Dr. David M. Altshuler M.D., Ph.D.Executive Vice President & Chief Scientific Officer
Dr. Ourania Tatsis Ph.D.Executive Vice President and Chief Regulatory & Quality Officer
NameRoleGenderDate of BirthPay
Dr. Reshma Kewalramani FASN, M.D.Chief Executive Officer, President & Director19736.54M
Mr. Stuart A. Arbuckle B.Sc.Executive Vice President & Chief Operating OfficerMale19663.15M
Mr. Charles F. Wagner Jr.Executive Vice President & Chief Financial OfficerMale19682.75M
Dr. David M. Altshuler M.D., Ph.D.Executive Vice President & Chief Scientific Officer19652.39M
Dr. Ourania Tatsis Ph.D.Executive Vice President and Chief Regulatory & Quality Officer19702.08M

Vertex Pharmaceuticals Incorporated Insider Trades

Date1 May
NameUpadhyay Suketu
RoleDirector
TransactionAcquired
TypeA-Award
Shares796
Date1 May
NameUpadhyay Suketu
RoleDirector
TransactionDisposed
TypeD-Return
Shares1001
Date1 May
NameUpadhyay Suketu
RoleDirector
TransactionAcquired
TypeA-Award
Shares1001
Date1 May
NameThornberry Nancy
RoleDirector
TransactionAcquired
TypeA-Award
Shares398
Date1 May
NameThornberry Nancy
RoleDirector
TransactionAcquired
TypeA-Award
Shares1199
DateNameRoleTransactionTypeShares
1 MayUpadhyay SuketuDirectorAcquiredA-Award796
1 MayUpadhyay SuketuDirectorDisposedD-Return1001
1 MayUpadhyay SuketuDirectorAcquiredA-Award1001
1 MayThornberry NancyDirectorAcquiredA-Award398
1 MayThornberry NancyDirectorAcquiredA-Award1199

Discover More

Streamlined Academy

Vertex Pharmaceuticals Incorporated

NASDAQ

Market Cap.

109.14B

Avg. Volume

1.64M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Vertex Pharmaceuticals Incorporated News

Vertex Pharmaceuticals Incorporated Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Vertex Pharmaceuticals Incorporated Earnings & Revenue

Vertex Pharmaceuticals Incorporated Income

Vertex Pharmaceuticals Incorporated Balance Sheet

Vertex Pharmaceuticals Incorporated Cash Flow

Vertex Pharmaceuticals Incorporated Financials Over Time

Vertex Pharmaceuticals Incorporated Executives

NameRole
Dr. Reshma Kewalramani FASN, M.D.Chief Executive Officer, President & Director
Mr. Stuart A. Arbuckle B.Sc.Executive Vice President & Chief Operating Officer
Mr. Charles F. Wagner Jr.Executive Vice President & Chief Financial Officer
Dr. David M. Altshuler M.D., Ph.D.Executive Vice President & Chief Scientific Officer
Dr. Ourania Tatsis Ph.D.Executive Vice President and Chief Regulatory & Quality Officer
NameRoleGenderDate of BirthPay
Dr. Reshma Kewalramani FASN, M.D.Chief Executive Officer, President & Director19736.54M
Mr. Stuart A. Arbuckle B.Sc.Executive Vice President & Chief Operating OfficerMale19663.15M
Mr. Charles F. Wagner Jr.Executive Vice President & Chief Financial OfficerMale19682.75M
Dr. David M. Altshuler M.D., Ph.D.Executive Vice President & Chief Scientific Officer19652.39M
Dr. Ourania Tatsis Ph.D.Executive Vice President and Chief Regulatory & Quality Officer19702.08M

Vertex Pharmaceuticals Incorporated Insider Trades

Date1 May
NameUpadhyay Suketu
RoleDirector
TransactionAcquired
TypeA-Award
Shares796
Date1 May
NameUpadhyay Suketu
RoleDirector
TransactionDisposed
TypeD-Return
Shares1001
Date1 May
NameUpadhyay Suketu
RoleDirector
TransactionAcquired
TypeA-Award
Shares1001
Date1 May
NameThornberry Nancy
RoleDirector
TransactionAcquired
TypeA-Award
Shares398
Date1 May
NameThornberry Nancy
RoleDirector
TransactionAcquired
TypeA-Award
Shares1199
DateNameRoleTransactionTypeShares
1 MayUpadhyay SuketuDirectorAcquiredA-Award796
1 MayUpadhyay SuketuDirectorDisposedD-Return1001
1 MayUpadhyay SuketuDirectorAcquiredA-Award1001
1 MayThornberry NancyDirectorAcquiredA-Award398
1 MayThornberry NancyDirectorAcquiredA-Award1199

Streamlined Academy

Website screenshot
HealthcareBiotechnology
vrtx.com

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated Financials

Table Compare

Compare VRTX metrics with:

   

Earnings & Growth

VRTX

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

VRTX

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

VRTX

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

VRTX

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Vertex Pharmaceuticals Incorporated Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)